We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diurnal Group Plc | LSE:DNL | London | Ordinary Share | GB00BDB6Q760 | ORD GBP0.05 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 27.30 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
17/5/2021 10:27 | If you consider 97p before the mms got wind of a placing then it is 50% down. | glasswala | |
17/5/2021 10:20 | From 97p to 62p. This is a diabolical. What has changed since 97p days to now. Has the news not got even better now with the China Chronocort extension. The BOD has the habit of destroying shareholder value by doing placing at ridiculously low ball placing and share raise. Its now over 10% below the latest placing and rights issye | glasswala | |
14/5/2021 17:11 | I think you are right, AIM. I did not this time, but the bigger picture has not changed here, as far as I can see anyway, which is the main thing. | lovewinshatelosses | |
14/5/2021 16:20 | Elton shares recovering . | s34icknote | |
14/5/2021 12:56 | It has really killed it. I bet hardly anyone took those placing shares after the last placing - it has to bounce soon. Extremely undervalued here. | aimmafia | |
14/5/2021 10:42 | Just like the previous placing, seemingly never ending erosion of the share price Thought they'd cracked it with the EU approval and China sales agreement but the Market doesn't appear interested. They're going to have to produce some encouraging numbers in the next set of results. | mufprat | |
14/5/2021 08:16 | Good question but haven't got the answer for that one aim . | s34icknote | |
14/5/2021 07:38 | From Eaton Results 13thMay General and Administrative (G&A) Expenses: G&A expenses for the first quarter of 2021 were $4.1 million compared to $2.6 million in the prior-year period. The increase was largely due to increased costs related to the commercialization of ALKINDI SPRINKLE. G&A expenses for the first quarter of 2021 included $0.7 million of non-cash expenses. Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2021 were $0.9 million compared to $6.3 million in the prior-year period. The prior-year period included $4.8 million of one-time licensing payments for the acquisition of marketing rights to ALKINDI SPRINKLE. | rosejs2 | |
14/5/2021 07:30 | What money do we receive from each new patient? | aimmafia | |
14/5/2021 07:25 | From Eton results 13 may ALKINDIĀ® SPRINKLEEton remains focused on the commercial launch of ALKINDI SPRINKLE in the United States. The first quarter of 2021 was the first full quarter of the product's launch. The company's sales representatives have already engaged with more than 90% of their initial targets in the pediatric endocrinology community, and sales representatives have been met with a positive reception from physicians, nurses, and caretakers.Although Initial sales force communications have largely been virtual due to COVID-19 related restrictions, certain physicians' offices and hospitals have recently begun accepting in-person meetings. Given the expectation for higher conversion rates on in-person meetings, Eton has adopted a sales force strategy that focuses resources most heavily in states where in-person meetings are taking place, rather than the traditional regional allocation of territories. The new strategy will allow all sales representatives to focus on maximizing in-person meetings, even if their previously assigned geography comprises states that are not accepting in-person visits. Eton will continue to refine the resource allocation in the coming weeks and months as additional states begin accepting in-person visits.In April, Eton presented virtually at the Pediatric Endocrinology Nursing Society national conference and the Pediatric Endocrinology Society annual meeting, the first two conferences since the product's launch.The company has seen strong adoption of ALKINDI SPRINKLE, and prescriptions continue to grow month over month. Over 100 new patient prescriptions have been written this year, and the company continues to work towards its goal of more than 400 new patient prescriptions by the end of the year. | s34icknote | |
14/5/2021 07:08 | And we still haven't had any money from them? | aimmafia | |
14/5/2021 06:57 | Eton numbers out yesterday aiming for 400 new prescriptions this year 100 signed to date | best1467 | |
13/5/2021 19:21 | 7 new patients a day | s34icknote | |
13/5/2021 17:14 | Actually stand corrected 385000 is worldwide birth rate 45000 in china .Second to India . | s34icknote | |
13/5/2021 14:33 | It's correct across the planet but not for territories covered by DNL | aimmafia | |
13/5/2021 14:05 | I would check that daily birth rate it sounds extremley incorrect | best1467 | |
13/5/2021 09:10 | Its even more funny that the pis are selling and the iis are mopping up the shares. | aimmafia | |
12/5/2021 21:58 | Funny wording 1 in 6000 births . Doesn't sound like much .But then again 385000 daily biths that's 64 new patients a day !!! | s34icknote | |
12/5/2021 13:54 | Is it to do with the dilution cross a threshold? | aimmafia | |
12/5/2021 12:57 | Sizeable TR1 notification. Wonder what's going on there? | amunro | |
12/5/2021 12:18 | Chart looks very nice to my eyes. And, yes, it looks like big investors will continue to buy. But I suspect even a trader would be able to sell fairly soon at around a quid. | small crow | |
12/5/2021 08:39 | Mr 8751 buying in and selling out at a loss. Comical | aimmafia | |
12/5/2021 08:32 | Spread has now closed so that is good. To be fair I don't even know 1) why I am surprised and 2) I'm even looking as todays price action is irrelevant to my long term hold | aimmafia | |
12/5/2021 08:27 | A 10% opening spread leads me to believe IIs have not yet finished buying. MMs will continue to try and suppress interest. | mufprat |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions